SHORT COMMUNICATION   Free access

Minerva Urology and Nephrology 2021 December;73(6):845-8

DOI: 10.23736/S2724-6051.20.03683-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Androgen deprivation therapy prescription, blood and bone-density testing in a French population-based study exploring adherence to the French prostate cancer guidelines

Lucie-Marie SCAILTEUX ^{1, 2} ✉, Frédéric BALUSSON ², Emmanuel OGER ^{1, 2}, Sébastien VINCENDEAU ³, Romain MATHIEU ^{3, 4}

¹ Department of Clinical Pharmacology, Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Rennes University Hospital, Rennes, France; ² Pharmacoepidemiology and Health Services Research, University of Rennes, Rennes, France; ³ Department of Urology, University Hospital of Rennes, Rennes, France; ⁴ Inserm, EHESP, CHU Rennes, Institut de Recherche en Santé, Environnement et Travail - IRSET, University of Rennes, Rennes, France

The safety profile of androgen deprivation therapy (ADT) is well known, and cardiovascular and osteoporosis risk factors should be assessed before ADT initiation. In order to examine whether the French Committee of Urologic Oncology Prostate Cancer (PCa) Guidelines were properly followed by clinicians, including urologists, oncologists and radiotherapists, we used a nationwide comprehensive cohort of prostate cancer patients, who were new ADT users in 2011 and were followed-up to 2013. Reimbursements for biological examinations and prescribers were identified, as well as PCa specialist consultations at drug initiation. Our results in this French cohort showed that the proportions of patients resorting to specialized care between one year and 3 months before ADT initiation and in the 6 months following was around 40% for fasting glucose and 30% for lipid assessments. Bone densitometry was performed in approximately 1% of patients. In the 12 months after ADT initiation, 75% of the patients were seen by a urologist and about 47% by an oncologist or a radiotherapist. Overall, there is still room for improvement in terms of ADT monitoring by clinicians and in the information provided to general practitioners and patients regarding the expected adverse effects of this treatment.

KEY WORDS: Prostatic neoplasms; Safety; Hematologic tests